Short answer
Surgery Partners, Inc. (SGRY) filed its Q2 2026 10-Q quarterly report on Aug 10, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $849M (up 2.7% year over year) with net income of −$15M.
Q2 2026 key financials · XBRL
- Revenue
- $849M
- +2.7% YoY · +4.7% QoQ
- Net income
- −$15M
- −500.0% YoY · +58.2% QoQ
- Operating margin
- 12.0%
- EPS (diluted)
- −$0.12
- −500.0% YoY · +57.1% QoQ
Source: XBRL data from the Surgery Partners, Inc. (SGRY) Q2 2026 10-Q on SEC EDGAR. USD.
Surgery Partners, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q2 revenue $848.9M, up 2.7% YoY from $826.2M; same-facility revenue up 5.0%
- Operating margin 12.0% vs 13.5% YoY; net loss $15.0M vs $2.5M
- Best case mix orthopedics and pain management at 40.1%; ophthalmology fell to 20.8% from 22.2%
- Cash $216.7M vs $239.9M at December 31; Revolver capacity $617.8M
- Operating cash flow $71.0M vs $87.3M; economic uncertainty, inflation, supply-chain risks and interest rates remain headwinds
Risk Factors
- No material changes to 2025 Form 10-K risk factors
- No newly added risk factor or quarter-specific trigger disclosed
- No updated regulatory, legal, or compliance risk disclosed
- No new operational, competitive, or market risk disclosed
- No new liquidity, debt, currency, or concentration risk disclosed
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Surgery Partners, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.